Premium
Serum 25‐hydroxyvitamin D and lung cancer risk
Author(s) -
Weinstein Stephanie J,
Yu Kai,
Horst Ronald L,
Parisi Dominick,
Virtamo Jarmo,
Albanes Demetrius
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.214.7
Subject(s) - lung cancer , medicine , vitamin d and neurology , odds ratio , confidence interval , nested case control study , cancer , cohort , cohort study , gastroenterology , endocrinology
We investigated the relationship between circulating 25‐hydroxyvitamin D [25(OH)D] and lung cancer risk in a case‐control study nested within the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study cohort of Finnish male smokers. Based on month of blood collection, 500 lung cancer cases were randomly selected, and 500 controls were matched to cases on age (+/− 1 yr) and blood collection date (+/− 30 days). Multivariate‐adjusted conditional regression models with season‐specific and season‐standardized quintiles of 25(OH)D, were used to account for the seasonal variation in 25(OH)D concentrations. Further, models were stratified on season of blood collection. Pre‐defined cutpoints of 25(OH)D, based on clinical definitions, were also examined. Circulating 25(OH)D was not associated with lung cancer risk overall; for example, odds ratio = 1.08 (95% confidence interval 0.67–1.75) for the highest vs. lowest season‐specific quintile of 25(OH)D. Inverse associations were suggested for subjects with winter blood collections, however, with trend test p‐values of 0.01, 0.05, and 0.07 for pre‐determined, season‐specific, and season‐standardized categories, respectively. Higher circulating vitamin D, measured when vitamin D synthesis in skin is reduced (i.e., during darker months), may be associated with reduced risk of lung cancer. Supported by the Intramural Research Program of the NIH and the NCI.